MX336384B - Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal. - Google Patents

Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal.

Info

Publication number
MX336384B
MX336384B MX2011004031A MX2011004031A MX336384B MX 336384 B MX336384 B MX 336384B MX 2011004031 A MX2011004031 A MX 2011004031A MX 2011004031 A MX2011004031 A MX 2011004031A MX 336384 B MX336384 B MX 336384B
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
kidney disorders
kidney
Prior art date
Application number
MX2011004031A
Other languages
English (en)
Other versions
MX2011004031A (es
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008905378A external-priority patent/AU2008905378A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of MX2011004031A publication Critical patent/MX2011004031A/es
Publication of MX336384B publication Critical patent/MX336384B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición que comprende una cantidad farmacéutica efectiva de uno o más fragmentos de péptido intestinal vaso activo (VIP) funcionales seleccionados de VIP(10-28) (SEQ ID NO: 2), VIP (4-12) (SEQ ID NO: 3), VIP (4-16) (SEQ ID NO: 4), VIP (4-20) (SEQ ID NO: 5), VIP (4-24) (SEQ ID NO:6), VIP (6-10) (SEQ ID NO: 7), VIP (6-12) (SEQ ID NO: 8), VIP (6-16) (SEQ ID NO:9 ), VIP (6-20) (SEQ ID NO: 10), VIP (6-24) (SEQ ID NO:11) o sustituciones conservadoras de éstos para su uso en el tratamiento terapéutico de fibrosis renal.
MX2011004031A 2008-10-17 2009-10-16 Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal. MX336384B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008905378A AU2008905378A0 (en) 2008-10-17 Compositions and methods for treatment of kidney disorders
PCT/AU2009/001367 WO2010042997A1 (en) 2008-10-17 2009-10-16 Compositions and methods for treatment of kidney disorders

Publications (2)

Publication Number Publication Date
MX2011004031A MX2011004031A (es) 2011-06-27
MX336384B true MX336384B (es) 2016-01-18

Family

ID=42106133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004031A MX336384B (es) 2008-10-17 2009-10-16 Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal.

Country Status (19)

Country Link
US (2) US8569235B2 (es)
EP (1) EP2349320B1 (es)
JP (1) JP2012505835A (es)
KR (1) KR101671406B1 (es)
CN (1) CN102186496A (es)
AU (1) AU2009304595B2 (es)
BR (1) BRPI0914504B8 (es)
CA (1) CA2740989C (es)
DK (1) DK2349320T3 (es)
ES (1) ES2603963T3 (es)
HK (1) HK1160598A1 (es)
IL (2) IL212353A0 (es)
MX (1) MX336384B (es)
MY (1) MY160560A (es)
NZ (2) NZ592612A (es)
RU (1) RU2519124C2 (es)
SG (1) SG10201501316VA (es)
WO (1) WO2010042997A1 (es)
ZA (1) ZA201103572B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2783697T3 (en) * 2005-12-09 2017-04-10 Vectus Biosystems Ltd VIP Fragments and uses thereof
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
KR101671406B1 (ko) * 2008-10-17 2016-11-01 벡투스 바이오시스템즈 리미티드 신장 장애 치료용 조성물 및 방법
US8729020B2 (en) 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
CN104130663B (zh) * 2014-06-27 2017-01-04 南安市永腾技术咨询有限公司 一种用于包装机的金属防腐漆及其制备方法
KR102554476B1 (ko) * 2015-03-18 2023-07-10 벡투스 바이오시스템즈 리미티드 신장 및／또는 간 질환 치료용 조성물
US9779043B2 (en) 2015-11-16 2017-10-03 International Business Machines Corporation Techniques for handling queued interrupts in a data processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253645A1 (en) * 2002-06-12 2003-12-31 The Board Of Trustees Of The University Of Illinois Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds
AU2003284428B2 (en) * 2002-11-27 2010-08-26 Ils Inc. Peptides and medicinal compositions containing the same
WO2005120545A1 (en) * 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
DK2783697T3 (en) 2005-12-09 2017-04-10 Vectus Biosystems Ltd VIP Fragments and uses thereof
KR101671406B1 (ko) * 2008-10-17 2016-11-01 벡투스 바이오시스템즈 리미티드 신장 장애 치료용 조성물 및 방법
US8729020B2 (en) * 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments

Also Published As

Publication number Publication date
BRPI0914504B8 (pt) 2021-05-25
ES2603963T3 (es) 2017-03-02
AU2009304595A1 (en) 2010-04-22
BRPI0914504B1 (pt) 2020-11-10
RU2011114857A (ru) 2012-11-27
JP2012505835A (ja) 2012-03-08
CA2740989A1 (en) 2010-04-22
IL235888A (en) 2017-08-31
EP2349320A1 (en) 2011-08-03
RU2519124C2 (ru) 2014-06-10
WO2010042997A1 (en) 2010-04-22
EP2349320B1 (en) 2016-06-22
US8569235B2 (en) 2013-10-29
KR20110095266A (ko) 2011-08-24
BRPI0914504A2 (pt) 2016-01-12
CN102186496A (zh) 2011-09-14
DK2349320T3 (en) 2016-09-26
AU2009304595B2 (en) 2015-02-05
MX2011004031A (es) 2011-06-27
US20110218149A1 (en) 2011-09-08
CA2740989C (en) 2016-07-12
EP2349320A4 (en) 2012-12-26
US9238054B2 (en) 2016-01-19
MY160560A (en) 2017-03-15
ZA201103572B (en) 2012-01-25
HK1160598A1 (zh) 2012-08-10
SG10201501316VA (en) 2015-05-28
KR101671406B1 (ko) 2016-11-01
NZ603602A (en) 2013-09-27
US20140080758A1 (en) 2014-03-20
NZ592612A (en) 2013-01-25
IL212353A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MY160560A (en) Compositions and methods for treatment of kidney disorders
TW200730538A (en) VIP fragments and methods of use
WO2007092622A3 (en) Compositions and methods for treating bone
MX2012002269A (es) Metodos y composiciones para el tratamiento de trastornos fibroticos pulmonares.
TW200716646A (en) (S)-N-methylnaltrexone
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
JO2576B1 (en) Antibodies
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2009129246A3 (en) Compositions and methods for preparing and using same
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
TW200740844A (en) Novel MAdCAM antibodies
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2008106228A3 (en) Methods and compositions for normalizing meibomian gland secretions
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MX350046B (es) Tratamientos para trastornos gastrointestinales.
JO3358B1 (ar) معالجات حساسية العيون
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor